Pomerantz LLP is investigating Omeros Corporation for potential securities fraud following two negative opinions from the European Medicines Agency (EMA) on its drug narsoplimab for treating TA-TMA. The EMA's initial rejection in June 2026 caused Omeros's stock to drop 19.12%, and a subsequent rejection in October led to a further 13.78% decline. This legal probe could impact investor confidence and the company's future regulatory efforts. Investors are advised to contact Pomerantz LLP for more information on joining the class action lawsuit.
Regarding the investigation into Omeros Corporation, here is Pluang's snapshot of the health sector as of Oct 29, 2026 20:51 WIB: Out of 150 priced US health stocks, 126 rose and 24 fell today. Notable movers include Eli Lilly And Co (LLY) at USD 1,387.98 with a 7.70% increase and a Pluang order activity of 29% Sell / 71% Buy, ClearPoint Neuro Inc (CLPT) at USD 11.20 up 6.06% with balanced order activity, and Baxter International Inc (BAX) at USD 24.09 down 5.38%.
Naples Comprehensive Health (NCH) has completed the first tricuspid valve repair in the US using the PASCAL Precision system following FDA approval. This minimally invasive catheter-based procedure offers a new treatment option for patients with seve...
Immunocore Holdings will present Phase 1/2 clinical trial data for brenetafusp alone and combined with KIMMTRAK in treating metastatic uveal melanoma at the 2026 Society for Immunotherapy of Cancer meeting. This trial evaluates safety and efficacy in...
Collegium Pharmaceutical and Boston Legacy FC have extended their partnership to include youth coach training, an annual Sports for All Summit, and sensory inclusion programs aimed at supporting neurodivergent children, especially those with ADHD, in...
Gilat Satellite Networks announced that its CEO Adi Sfadia and CFO Gil Benyamini will attend the Deutsche Bank Global Space and Defense Tech Summit on November 18, 2026, in New York City. The event will feature one-on-one and group meetings, providin...
Boralex Inc. has acquired Wind2, a UK-based renewable energy developer with about 350 MW of advanced wind projects across Scotland, England, and Wales. This acquisition strengthens Boralex's presence and capabilities in the UK, aligning with its stra...
